Literature DB >> 8273549

Immunosuppressive therapy of organ-specific nephritic autoimmune diseases with 15-deoxyspergualin.

H U Schorlemmer1, H P Neubauer, J Czech, G Dickneite.   

Abstract

According to its immunopharmacological profile, 15-deoxyspergualin (15-DOS) has been investigated as to its disease-modifying activity on HgCl2-induced glomerulonephritis (GN) and on tubulointerstitial nephritis (TIN) in Brown-Norway rats. Both models are induced autoimmune disorders in which afflicted animals display high levels of serum autoantibodies directed against the glomerular or tubular basement membrane (GBM or TBM), respectively. The diseases are manifested by high serum creatinine and urea levels with severe proteinuria. In the model of HgCl2-GN, administration of 15-DOS clearly led to a reduction of proteinuria and decreased the amount of rat IgG attached to the GBM. Furthermore, a therapeutic effect could be demonstrated when 15-DOS was given after the appearance of clinical symptoms. Not only urine-protein values but also anti-laminin antibodies returned to normal levels. Also in the experimental TIN-model, 15-DOS, either given during the induction phase, or even late in the onset of the disease, strongly prevented the proteinuria of this autoimmune disease and inhibited the formation of autoantibodies to TBN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8273549     DOI: 10.1007/bf01972741

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  5 in total

1.  Treatment of acute rejection episodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin.

Authors:  H U Schorlemmer; G Dickneite; F R Seiler
Journal:  Transplant Proc       Date:  1990-08       Impact factor: 1.066

2.  Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats.

Authors:  G H Thoenes; T Sitter; K H Langer; R R Bartlett; R Schleyerbach
Journal:  Int J Immunopharmacol       Date:  1989

3.  Induction of anti-glomerular basement membrane antibodies in the Brown-Norway rat by mercuric chloride.

Authors:  C Sapin; E Druet; P Druet
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

4.  Immunosuppressive activity of 15-deoxyspergualin (15-DOS) on various models of rheumatoid arthritis.

Authors:  H U Schorlemmer; R R Bartlett; R Schleyerbach; F R Seiler
Journal:  Drugs Exp Clin Res       Date:  1991

5.  15-Deoxyspergualin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE).

Authors:  H U Schorlemmer; F R Seiler
Journal:  Agents Actions       Date:  1991-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.